This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback
Trial record 1 of 1 for:    NCT00174889
Previous Study | Return to List | Next Study

Pregnenolone in the Management of Schizophrenia Patients

This study has been completed.
Beersheva Mental Health Center
Information provided by:
Sha’ar Menashe Mental Health Center Identifier:
First received: September 9, 2005
Last updated: May 20, 2008
Last verified: May 2008
Pregnenolone is a "neurosteroid" and possesses intrinsic behavioral and brain effects in animals, affecting the GABA(A) and other receptors. Pregnenolone is serves as the precursor for dehydroepiandrosterone (DHEA) and its sulfate ester (DHEAS). There is evidence of efficacy of DHEA augmentation in schizophrenia, we therefore sought to examine the efficacy of augmentation of antipsychotic treatment of schizophrenia patients with pregnenolone. It is hypothesized that the combined effect of antipsychotic agents and pregnenolone would be beneficial in the treatment of negative,depressive, and cognitive symptoms.

Condition Intervention Phase
Schizophrenia Drug: Pregnenolone Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Pregnenolone Augmentation in the Management of Schizophrenia Patients: a Randomised Double-Blind Placebo-Controlled Trial

Resource links provided by NLM:

Further study details as provided by Sha’ar Menashe Mental Health Center:

Primary Outcome Measures:
  • The computerized Cambridge Neuropsychological Test Automated Battery (CANTAB).
  • The Positive and Negative Syndrome Scale.
  • The Scale for the Assessment of Negative Symptoms.
  • The Calgary Depression Scale for Schizophrenia.
  • The Hamilton Scale for Anxiety.
  • Extrapyramidal Symptom Rating Scale.
  • Barnes Akathisia Scale.
  • Abnormal Involuntary Movement Scale.

Secondary Outcome Measures:
  • The Scale to assess Unawareness of Mental Disorder (SUMD, Amador, 1999).

Estimated Enrollment: 60
Study Start Date: January 2005
Study Completion Date: May 2007
Detailed Description:
Either pregnenolone (30 mg/d or 200 mg/d), DHEA (400 mg/d)or placebo will be added to regular treatment for 8 weeks. Subjects will be assessed at baseline and after 2, 4, 6 and 8 weeks of treatment. An extensive battery of research instruments will be used for assessment of the following domains of interest: psychopathology, insight, side effects, and cognitive functions. Plasma pregnenolone, DHEA(S), cortisol and other relevant steroids will be assayed at baseline, 2, 4, 6 and 8 weeks of treatment. Efficacy and safety of augmentation of antipsychotic treatment with pregnenolone will be analyzed.

Ages Eligible for Study:   20 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • DSM-IV criteria for schizophrenia or schizoaffective disorder
  • Ability and willingness to sign informed consent for participation in the study

Exclusion Criteria:

  • Evidence of organic brain damage, mental retardation, alcohol or drug abuse
  • Prostate nodules or cancer.
  • Moderate symptoms of benign prostatic hypertrophy such as hesitancy, urgency, frequent voiding and feeling of incomplete voiding.
  • History of ischemic cardiac disease.
  • Renal disease.
  • Hepatic dysfunction.
  • Women with a history of carcinoma of the breast, or any women with a family history of the following: premenopausal breast cancer or bilateral breast cancer in a first degree relative; multiple family members (greater than three relatives) with postmenopausal breast cancer.
  • Women with a history of uterine cancer.
  • Patients with a known hypersensitivity to androgens.
  • Pregnant women.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00174889

Sha'ar Menashe Mental Health
Hadera, Israel, 38814
Sponsors and Collaborators
Sha’ar Menashe Mental Health Center
Beersheva Mental Health Center
Principal Investigator: Michael S. Ritsner, MD, PhD Sha’ar Menashe Mental Health Center
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Michael S Ritsner, Shaar-Menashe MHC Identifier: NCT00174889     History of Changes
Other Study ID Numbers: PREG 6/2004
Study First Received: September 9, 2005
Last Updated: May 20, 2008

Keywords provided by Sha’ar Menashe Mental Health Center:

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders processed this record on September 21, 2017